Abacavir

證據等級: L5

預測適應症: 3 個

Abacavir: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) with well-established use in antiretroviral therapy for HIV-1 infection. The TxGNN model predicts it may be effective for Simian Immunodeficiency Virus (SIV) Infection, with 0 clinical trials and 1 publication currently supporting this direction. The mechanistic basis is strong in principle, but clinical applicability is largely limited to non-human primate models and occupational exposure scenarios.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (antiretroviral combination therapy)
Predicted New Indication	Simian Immunodeficiency Virus (SIV) Infection
TxGNN Prediction Score	99.79%
Evidence Level	L4
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the evidence pack. Based on the clinical context across the available evidence, Abacavir is an NRTI whose active metabolite — carbovir triphosphate — competitively inhibits the viral reverse transcriptase enzyme and terminates proviral DNA chain elongation. This mechanism is the cornerstone of its established efficacy in HIV-1 infection.

SIV (Simian Immunodeficiency Virus) and HIV-1 are both members of the Lentivirus genus and share high sequence homology in their reverse transcriptase domains. Because Abacavir’s active metabolite directly targets the RT active site — a structurally conserved region across lentiviruses — its inhibitory activity is expected to extend to SIV RT via the same chain-termination mechanism. This cross-species extrapolation is mechanistically sound and not merely speculative.

However, the practical clinical context is significantly limited. SIV primarily infects non-human primates; it is not a human pathogen under ordinary circumstances. Therapeutic relevance for Abacavir in this setting is therefore confined to: (1) animal model research for HIV pathogenesis and drug development, and (2) post-exposure prophylaxis in occupational accidents involving SIV-infected primates. These are niche scientific rather than mainstream clinical applications.

Clinical Trial Evidence

Currently no related clinical trials registered for Abacavir in simian immunodeficiency virus infection.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15040537	2004	In vitro comparative study	Antiviral Therapy	Evaluated 16 approved antiretroviral drugs against HIV-2, SIV (mac251, B670), and SHIV strains; demonstrated that multiple NRTI-class drugs retain activity against SIV reverse transcriptase, providing direct in vitro evidence for cross-species antiviral susceptibility relevant to treatment and post-exposure prophylaxis guidance

India Market Information

Abacavir is currently not registered or marketed in India. No authorisation records are available.

Safety Considerations

Drug Interactions: A total of 93 drug interactions have been identified via DDInter. Key interactions include:

Interacting Drug	Interaction Level
Naltrexone	Moderate
Orlistat	Moderate
Morphine	Unknown
Metformin	Unknown
Prednisone	Unknown
Amphotericin B	Unknown
Sulfasalazine	Unknown
Vancomycin	Unknown

The majority of interactions are classified as “Unknown” severity, indicating limited characterisation data. The two moderate-level interactions (Naltrexone, Orlistat) warrant clinical attention when co-administered.

For complete warnings, contraindications, and precautions, please refer to the approved package insert (e.g., Ziagen® prescribing information), as this data was not available in the current evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic link between Abacavir and SIV is biologically coherent given the shared lentiviral RT structure, but clinical evidence is limited to a single in vitro comparative study with no registered clinical trials. Furthermore, SIV infection is not a human disease — the clinical use case is restricted to animal model research or rare occupational post-exposure scenarios, which substantially limits the drug repurposing value from a public health or commercial development perspective.

To proceed, the following is needed:

MOA data: Retrieve full DrugBank mechanism-of-action entry for Abacavir to complete the mechanistic rationale analysis
Safety data: Download and parse the approved package insert (e.g., from FDA or EMA) to obtain formal warnings, contraindications, and black-box alerts — currently a blocking data gap (DG001)
Preclinical activity data: Identify published in vivo studies confirming Abacavir activity against SIV in non-human primate models to upgrade evidence from L4 toward L3
Clinical context clarification: Define the specific use case (animal model support vs. occupational PEP) before proceeding with any further regulatory or development planning
India registration strategy: If clinical application is pursued (e.g., PEP guidelines), assess regulatory pathway under CDSCO for new indication filing, given that Abacavir is currently entirely unregistered in India
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.